Comprehensive investigation of alternative splicing and development of a prognostic risk score for prostate cancer based on six-gene signatures

Conclusion: Our comprehensive investigation of alternative splicing not only provided insight into the biological pathways of alternative splicing involved in the development of prostate cancer but also revealed new potential biomarkers for prognosticating as well as novel therapeutic targets for development of prostate cancer treatment.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

In this study, we found that the mutation, copy number alteration, and methylation status of PRKAR2B gene have no correlation with its expression level in PCa. Then, we identified two microRNAs (miR-200b-3p and miR-200c-3p) to be critical regulators of PRKAR2B expression in PCa. Notably, miR-200b-3p and miR-200c-3p expression were significantly downregulated in metastatic CRPC and negatively correlated with the expression level of PRKAR2B in PCa tissues. Moreover, we characterized X-Box Binding Protein 1 (XBP1) as a key transcription factor responsible for PRKAR2B expression in PCa. Importantly, miR-200b-3p/200c-3p or XBP1...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Conclusions: Introducing pre-biopsy mpMRI into our contemporary PCa diagnosis pathway increased the diagnostic yield of transrectal biopsy by increasing the prostate cancer detection. This enabled the introduction of clinically significant prostate cancer (csPCa) treatment. mpMRI application also allowed biopsy to be avoided among patients with no csPCa. PMID: 31969912 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Authors: Kind S, Merenkow C, Büscheck F, Möller K, Dum D, Chirico V, Luebke AM, Höflmayer D, Hinsch A, Jacobsen F, Göbel C, Weidemann S, Fraune C, Möller-Koop C, Hube-Magg C, Clauditz TS, Simon R, Sauter G, Wilczak W, Bawahab AA, Izbicki JR, Perez D, Marx A Abstract Syndecan-1 (CD138) is a transmembrane proteoglycan known to be expressed in various normal and malignant tissues. It is of interest because of a possible prognostic role of differential expression in tumors and its role as a target for indatuximab, a monoclonal antibody coupled with a cytotoxic agent. To comprehensively analyze ...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Publication date: April 2020Source: Biomedicine &Pharmacotherapy, Volume 124Author(s): Yong Zhou, Bo Tian, Jinming Tang, Jie Wu, Hui Wang, Zhining Wu, Xu Li, Desong Yang, Baihua Zhang, Yuhang Xiao, Ying Wang, Junliang Ma, Wenxiang Wang, Min SuAbstractLong noncoding RNAs (lncRNAs) are a group of RNAs that lack protein-coding ability, with lengths greater than 200 nucleotides. Increasing evidence has indicated that they mediate multiple physiological and pathological processes by regulating gene expression at the epigenetic, transcriptional, post-transcriptional, and translational levels. The deregulation of lncRNAs was ...
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Introduction: Small cell prostate cancer (SCPC) is a rare histologic subtype of prostate cancer, for which the optimal staging strategy remains unclear. Method: The Surveillance, Epidemiology, and End Results database was used to analyze the incidence and outcomes of SCPC between the years 2004 through 2016. Limited-stage SCPC (LS-SCPC) was defined as SCPC without any metastasis regardless of local invasion. Extensive stage SCPC (ES-SCPC) was defined as any metastasis to lymph nodes and/or to distant organs. Result: A total of 403 SCPC patients were included in the study cohort, accounting for 0.056% of all prostat...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
Purpose: The purpose of this study was to evaluate the treatment efficacy of stereotactic body radiotherapy (SBRT) in oligometastatic prostate cancer recurrence and to assess whether there is any relationship between biologically effective dose (BED) and local control (LC). Materials and Methods: Eligible studies were identified on Medline, Embase, and the Cochrane Library, and the proceedings of annual meetings through May 2019 were also identified. A meta-regression analysis was performed to assess whether there is a relationship between BED and LC. In the univariate analysis, studies were separated by the study des...
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Genitourinary Source Type: research
Authors: Jia Y, Gao Y, Dou J Abstract Effects of miR-129-3p on the biological functions of prostate cancer cells through the targeted regulation of Smad3 were investigated. RT-PCR was used to detect the expression levels of miR-129-3p in prostate cancer tissues and cells and its target gene Smad3 mRNA determined by bioinformatics prediction. Correlation between miR-129-3p and Smad3 was analyzed. MTT assay, cell invasion detection, and apoptosis detection were conducted to detect the effects of miR-129-3p and Smad3 on the proliferation, invasion, and apoptosis of prostate cancer cells. The results of RT-qPCR showed ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Androgen receptor targeted therapies have emerged as an effective tool to manage advanced prostate cancer (PCa). Nevertheless, frequent occurrence of therapy resistance represents a major challenge in the clin...
Source: Cell Communication and Signaling - Category: Molecular Biology Authors: Tags: Research Source Type: research
Oncogene, Published online: 24 January 2020; doi:10.1038/s41388-020-1163-1Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
ConclusionsOver the long term after RARP for PCA, the risk of hospital readmission is associated with ePLND. In patients who underwent RARP and ePLND, 4.4% of them had a readmission, compared to RARP alone, in which only 0.8% of cases had a readmission. When ePLND is planned for staging pelvic lymph nodes, patients should be informed of the increased risk of hospital readmission.
Source: World Journal of Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Prostate Cancer